Beta-containing COVID-19 booster vaccine found to cross-neutralize
4.7 (472) · $ 24.50 · In stock
A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
A case for updating COVID vaccines with beta variant spike sequences
AstraZeneca, Pfizer vaccines effective against Delta COVID-19 variants-study
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines - Mucosal Immunology
Exploring a variant-adapted SARS-CoV-2 recombinant protein vaccine
Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants - Liang - 2024 - Journal of Medical Virology - Wiley Online Library
Updated COVID-19 Boosters and XBB.1.5: What You Need to Know
Jean-François Toussaint on LinkedIn: #covid19
Neutralization of SARS-CoV-2 variants by NVX-CoV2373 vaccinee plasma.
Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8+ T cells against SARS-CoV-2 variants - ScienceDirect
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines
Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans
Moderna COVID-19 vaccine - Wikipedia
Dean Huang's Instagram, Twitter & Facebook on IDCrawl
:max_bytes(150000):strip_icc()/brano-QSuou3VAtf4-unsplash-de657fc5880046b493909ea2e02262dc.jpeg)
COVID-19 Booster Shots: Are They Variant-Specific?
